---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-073787"
form_type: "8-K"
ticker: null
cik: "0001567892"
company_name: "Keenova Therapeutics plc"
filed_at: "2026-06-15T12:00:39+00:00"
generated_at: "2026-06-15T12:07:23.957947+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Keenova Therapeutics to sell Percocet and Endocet businesses to Par Health for up to $250M

## Summary
- Upfront purchase price $25M; quarterly earnout payments over 5 years based on gross profit of the Business.
- Transaction expected to close in Q3 2026, subject to HSR clearance and other customary closing conditions.
- After closing, Keenova will no longer market, manufacture, or distribute opioid products.
- Consideration total up to ~$250M; deal includes Percocet and Endocet businesses sold to Par Health, Inc.

## SEC filing metadata
- accession: 0001104659-26-073787
- form_type: 8-K
- cik: 0001567892
- company_name: Keenova Therapeutics plc
- filed_at: 2026-06-15T12:00:39+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567892/000110465926073787/0001104659-26-073787-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567892/000110465926073787/tm2617927d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-073787
- JSON: https://secwatch.observer/filing/0001104659-26-073787.json
- Plain text: https://secwatch.observer/filing/0001104659-26-073787.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.